98019-60-4

Usage

Uses

Used in Pharmaceutical Industry:
5-ISOXAZOLEMETHANOL is used as a key building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its presence in the molecular structure of these compounds can enhance their biological activity and medicinal properties.
Used in Agrochemical Industry:
In the agrochemical sector, 5-ISOXAZOLEMETHANOL is utilized as a fundamental component in the creation of pesticides, herbicides, and other crop protection agents. Its incorporation into these products can improve their effectiveness in protecting crops from pests and diseases.
Used in Organic Synthesis:
5-ISOXAZOLEMETHANOL serves as a heterocyclic bifunctional reagent in organic synthesis, enabling the formation of complex chemical structures. This application is crucial for researchers and manufacturers who aim to innovate and produce novel organic compounds with specific properties and functions.
Overall, 5-ISOXAZOLEMETHANOL's significance in the pharmaceutical and agrochemical industries, as well as in broader organic chemistry, stems from its ability to act as a versatile intermediate and reagent, facilitating the synthesis of a wide range of biologically relevant and chemically complex molecules.

Upstream product

• 7664-93-9 sulfuric acid 
• 15736-98-8 sodium cyanate 
• 107-19-7 propargyl alcohol 
• 21169-71-1 isoxazole-5-carboxylic acid 
• 99805-29-5 4-tetrahydropyran-2-yloxy-but-2-ynal-diethylacetal 
• 173850-41-4 5-isoxazolecarboxylic acid ethyl ester 

Downstream Products

• 21169-71-1 isoxazole-5-carboxylic acid 
• 16401-14-2 5-isoxazolecarboxaldehyde 
• 57777-33-0 5-(chloromethyl)isoxazole 
• 144186-59-4 ((5-Isoxazolyl)methyl)-(4-nitrophenyl)carbonate 
• 69735-35-9 5-bromomethyl isoxazole 

Relevant academic research and scientific papers

SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

PYRROLOPYRAZINE KINASE INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

NOVEL ANDROGENS

The compounds of the subject invention have a structure according to formula I: wherein X is S or SO2; R1 is (1C-6C)alkyl, (3C-6C)alkenyl, or (3C-6C)alkynyl, each optionally subst ituted with (3C-6C)cycloalkyl, OH, OC(O)(1C-4C)alkyl, (1C- 4C)alkoxy, halogen, cyano, formyl, C(O)(1C-4C)alkyl, CO2H, CO2(1C- 4C)alkyl, C(O)NR5R6, S(O)(1C-4C)alkyl or S(O)2(1C-4C)alkyl; R2 is hydrogen, (1C-4C)alkyl or C(O)(1C-4C)alkyl; R3 is a phenyl group optionally substituted with (1C-4C)alkyl, (1C-4C)fluoroalkyl, (1C-4C)alkoxy, (1C-4C)fluoroalkoxy, halogen, cyano or nitro; or R3 is a 5- or 6-membered aromatic heterocyclic ring structure optionally substituted with (1C-4C)alkyl, (1C-4C)fluoroalkyl, (1C-4C)alkoxy, halogen or cyano; R4 is a phenyl group or an aromatic 6-membered heterocycle, substituted at the ortho position with 1-hydroxy(1C-4C)alkyl, (1C-4C)alkoxy, C(O)(1C- 4C)alkyl, CO2(1C-4C)alkyl, C(O)NH2, cyano, nitro, or CH=NOR7, and optionally further substituted with (1C-2C)alkyl, (1C-2C)fluoroalkyl or halogen; R5 is 2-pyridyl optionally substituted with (1C-2C)alkyl, (1C- 2C)fluoroalkyl or halogen; or R5 and R6 are independently hydrogen or (1C-4C)alkyl; R7 is hydrogen or C(O)(1C-4C)alkyl; R8 , R9 , R10 are independently hydrogen, (1C-2C)alkyl, fluoro or chloro; or a salt or hydrate form thereof.

RETROVIRAL PROTEASE INHIBITING COMPOUNDS

A retroviral protease inhibiting compound of the formula: STR1 is disclosed wherein R 1, R 2, R 5, R 6, Y m and Y' n are herein defined.

Regioisomeric 3-, 4- and 5-aminomethyl isoxazoles: Synthesis and muscarinic activity

A series of 3-, 4- and 5-aminomethyl isoxazoles and isoxazoles with one or two additional methyl groups at the heterocycle were synthesized in order to investigate the structural requirements, ie heterocyclic moiety, regiochemistry and length of an aminoalkyl unit, for muscarinic activity. This was assayed on isolated rabbit vas deferens (M1 receptor subtype) and isolated guinea-pig atrium (M2 receptor subtype) and ileum (M3 receptor subtype). The isoxazoles tested are one to three orders of magnitude less active than furane or oxadiazole derivatives, having similar structural characteristics except for the heterocycle. Thus, the differences in molecular point charges and charge distribution contribute to the muscarinic activity of these compounds more than small differences in molecular shape and conformational energies.